DGAP-News: Siemens to market BioPorto's breakthrough kidney test
(firmenpresse) - BioPorto A/S
11.12.2012 14:03
---------------------------------------------------------------------------
Expectations for BioPorto Diagnostics have been high since the company launched
its anticipated blockbuster product almost two years ago - the kidney injury
test known as NGAL. Since then, BioPorto has worked towards solutions that
would ensure broad and early market access to the test. In this regard, the
first partnership on a global marketing level is now in place. This comes in
the form of an informal sales partnership with Siemens Healthcare Diagnostics
actively promoting BioPorto's NGAL test, while the distribution still flows
through BioPorto's sales channels.
The agreement translates into excellent synergy in that Siemens is one of the
world's largest suppliers of precisely the type of analyzers that BioPorto's
The NGAL Test(tm) is designed to run on. The partnership creates a win-win
scenario for the companies and customers. Siemens will have access to a test
that their customers demand and a strategic advantage over competitors who do
not offer NGAL in their test portfolios. Siemens analyzers are widely used in
hospital laboratories, which ensures that the test will be economical to
implement and readily available to doctors worldwide. From BioPorto's point of
view, it is hard to think of a faster and more convenient way to reach
customers.
Such an informal but bespoke partnership between a reagent supplier (BioPorto)
and an instrument supplier (Siemens) is far from unique in the diagnostic
industry. Introduction of a new diagnostic test is a long and tough process,
and being first-to-market can be crucial.
But Siemens are not the only one who has set their sights on BioPorto's
breakthrough test. Roche Diagnostics also confirmed their interest in NGAL and
BioPorto continues to discuss possibilities for collaboration with more leading
diagnostic companies.
About NGAL - the acute kidney injury test
Every year about 13 million people suffer from acute kidney injury of which
about 4 million die.
Despite this, progress in diagnosing kidney injury has been stagnant the past
60 years.
The current methods provide the first signal of kidney failure one to three
days after the kidney has been damaged. NGAL on the other hand, can detect
instantaneous damage, thus giving the physician an opportunity to make crucial
decisions before kidney damage evolves into a potentially fatal kidney failure.
Furthermore, cost-benefit analyses show that NGAL measurements will contribute
towards cost-savings for hospitals when managing kidney injury-patients.
Further details
Thea Olesen, CEO, BioPorto
Telephone +45 45 29 00 00; e-mail info(at)bioporto.com
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales channels and
partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on
the NASDAQ OMX Copenhagen stock exchange.
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=412987
News Source: NASDAQ OMX
11.12.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: BioPorto A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0011048619
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Orestone Drills Four Hundred Meters of Porphyry Mineralization at Captain Project
Datum: 11.12.2012 - 14:03 Uhr
Sprache: Deutsch
News-ID 211549
Anzahl Zeichen: 6899
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Siemens to market BioPorto's breakthrough kidney test"
steht unter der journalistisch-redaktionellen Verantwortung von
BioPorto A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
